![](/wp-content/uploads/2022/01/Other-Research-Resources-440x300-1.png")
Tweets
;
Do you have newly diagnosed #Glioblastoma? If so, you may be able to participate in this study of a new treatment approach. Learn more about EAF223/GABLE here: https://bit.ly/gable-trial
In #ClinicalTrial EA2222/PUMP, investigators are testing #PumpChemo in addition to SOC chemo versus SOC chemo alone for patients with unresectable #ColorectalCancer liver metastases. For more: https://bit.ly/ea2222-pump cc : @michael_lidsky
The EA8211/SOAR clinical study is testing a new treatment approach for patients with #KidneyCancer that has spread to 2-5 other places in the body. Learn more: https://bit.ly/ea8211-study #kcsm
About Us
The ECOG-ACRIN Cancer Research Group is a strong network of nearly 1300 academic and community-based cancer centers and hospitals in the United States and around the world. We design and conduct biomarker-driven research involving adults who have or are at risk of developing cancer. Learn More
Scientific Pursuits
We are dedicated to improving life for adults affected by cancer. Through our member sites, we are pursuing a robust clinical and translational research portfolio that focuses on precision oncology, immunotherapy, reducing over-treatment and over-diagnosis, leveraging novel biomarker platforms to inform therapeutic decision-making, and advancing standards of care in broad populations of cancer patients and those at risk. Learn More
ECOG-ACRIN by the Numbers
43
Active Clinical Trials
1400
Participating Institutions
67
International Sites
21000
Individual Members
Scientifically rigorous, broadly multidisciplinary, organizationally robust, and internationally respected, the Group is a vibrant component of the National Cancer Institute (NCI) National Clinical Trials Network (NCTN). In addition, we are a Research Base in the NCI Community Oncology Research Program (NCORP).
